Wall Street brokerages expect ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to announce earnings of ($0.41) per share for the current quarter, Zacks reports. Five analysts have made estimates for ACADIA Pharmaceuticals’ earnings. The highest EPS estimate is ($0.38) and the lowest is ($0.44). ACADIA Pharmaceuticals reported earnings of ($0.50) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 18%. The business is scheduled to report its next quarterly earnings report on Tuesday, November 5th.
According to Zacks, analysts expect that ACADIA Pharmaceuticals will report full year earnings of ($1.87) per share for the current year, with EPS estimates ranging from ($2.45) to ($1.71). For the next financial year, analysts forecast that the company will post earnings of ($1.35) per share, with EPS estimates ranging from ($2.74) to $0.45. Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that cover ACADIA Pharmaceuticals.
ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.46) by $0.08. ACADIA Pharmaceuticals had a negative return on equity of 70.97% and a negative net margin of 101.45%. The business had revenue of $83.21 million during the quarter, compared to analyst estimates of $72.50 million. During the same period last year, the company earned ($0.51) earnings per share. ACADIA Pharmaceuticals’s quarterly revenue was up 45.8% compared to the same quarter last year.
Several analysts recently issued reports on the company. HC Wainwright set a $60.00 price objective on ACADIA Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday. Canaccord Genuity raised shares of ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating and increased their target price for the stock from $29.00 to $50.00 in a research report on Tuesday. Needham & Company LLC increased their target price on shares of ACADIA Pharmaceuticals from $34.00 to $60.00 and gave the stock a “buy” rating in a research report on Monday. Stifel Nicolaus set a $39.00 target price on shares of ACADIA Pharmaceuticals and gave the stock a “hold” rating in a research report on Monday. Finally, Bank of America set a $31.00 target price on shares of ACADIA Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, July 31st. Four equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $43.79.
In other news, Director James M. Daly sold 30,000 shares of the firm’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $37.80, for a total value of $1,134,000.00. Following the sale, the director now directly owns 30,000 shares of the company’s stock, valued at $1,134,000. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Eric Alejandro Miller sold 4,645 shares of the firm’s stock in a transaction dated Wednesday, September 11th. The shares were sold at an average price of $41.18, for a total value of $191,281.10. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 63,112 shares of company stock worth $2,449,443. 29.40% of the stock is currently owned by company insiders.
Several large investors have recently modified their holdings of ACAD. Clearbridge Investments LLC acquired a new stake in ACADIA Pharmaceuticals during the first quarter worth about $27,000. Twin Tree Management LP acquired a new stake in ACADIA Pharmaceuticals during the first quarter worth about $29,000. Steward Partners Investment Advisory LLC acquired a new stake in ACADIA Pharmaceuticals during the second quarter worth about $42,000. Quantamental Technologies LLC acquired a new stake in ACADIA Pharmaceuticals during the second quarter worth about $57,000. Finally, NumerixS Investment Technologies Inc acquired a new stake in ACADIA Pharmaceuticals during the second quarter worth about $107,000. 97.38% of the stock is currently owned by institutional investors.
Shares of NASDAQ:ACAD opened at $40.34 on Friday. The company has a current ratio of 6.85, a quick ratio of 6.79 and a debt-to-equity ratio of 0.02. ACADIA Pharmaceuticals has a 1 year low of $13.51 and a 1 year high of $43.98. The business has a fifty day simple moving average of $28.11 and a 200 day simple moving average of $26.40. The firm has a market cap of $5.96 billion, a price-to-earnings ratio of -20.79 and a beta of 2.75.
ACADIA Pharmaceuticals Company Profile
ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
Recommended Story: Equal Weight Rating
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.